428 related articles for article (PubMed ID: 21094987)
1. A new method measuring the interaction between von Willebrand factor and coagulation factor VIII.
Karlman M; Holmström M; Wiman B
Thromb Res; 2011 Jan; 127(1):47-50. PubMed ID: 21094987
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
Miller CH; Kelley L; Green D
Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
[TBL] [Abstract][Full Text] [Related]
3. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications.
Casonato A; Pontara E; Zerbinati P; Zucchetto A; Girolami A
Am J Clin Pathol; 1998 Mar; 109(3):347-52. PubMed ID: 9495210
[TBL] [Abstract][Full Text] [Related]
4. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
Veyradier A; Caron C; Ternisien C; Wolf M; Trossaert M; Fressinaud E; Goudemand J
Haemophilia; 2011 Nov; 17(6):944-51. PubMed ID: 21371195
[TBL] [Abstract][Full Text] [Related]
5. Interaction of factor VIII and von Willebrand factor and the identification of type 2N von Willebrand disease.
Favaloro EJ
Thromb Res; 2011 Jan; 127(1):2-3. PubMed ID: 21084106
[No Abstract] [Full Text] [Related]
6. Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction.
Batlle J; Lourés E; Vila P; Hernández MC; Méndez JA; Torea J; Rendal E; Couselo MJ; Filgueira A; López Fernández MF
Ann Hematol; 1997 Sep; 75(3):111-5. PubMed ID: 9368480
[TBL] [Abstract][Full Text] [Related]
7. Measurement of von Willebrand factor-FVIII binding activity in patients with suspected von Willebrand disease type 2N: application of an ELISA-based assay in a reference laboratory.
Zhukov O; Popov J; Ramos R; Vause C; Ruden S; Sferruzza A; Dlott J; Sahud M
Haemophilia; 2009 May; 15(3):788-96. PubMed ID: 19298374
[TBL] [Abstract][Full Text] [Related]
8. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
9. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC
J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534
[TBL] [Abstract][Full Text] [Related]
10. Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents.
Caron C; Mazurier C; Goudemand J
Br J Haematol; 2002 Jun; 117(3):716-8. PubMed ID: 12028048
[TBL] [Abstract][Full Text] [Related]
11. Laboratory Testing for von Willebrand Factor: Factor VIII Binding (for 2N VWD).
Mohammed S; Favaloro EJ
Methods Mol Biol; 2017; 1646():461-472. PubMed ID: 28804848
[TBL] [Abstract][Full Text] [Related]
12. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.
López-Fernández MF; Blanco-López MJ; Castiñeira MP; Batlle J
Am J Hematol; 1992 May; 40(1):20-7. PubMed ID: 1566742
[TBL] [Abstract][Full Text] [Related]
13. Laboratory Testing for von Willebrand Factor: Factor VIII Binding for the Diagnosis or Exclusion of Type 2N von Willebrand Disease: An Update.
Favaloro EJ; Mohammed S; Vong R; Pasalic L
Methods Mol Biol; 2023; 2663():679-691. PubMed ID: 37204745
[TBL] [Abstract][Full Text] [Related]
14. Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy.
Nishino M; Nishino S; Sugimoto M; Shibata M; Tsuji S; Yoshioka A
Int J Hematol; 1996 Aug; 64(2):127-34. PubMed ID: 8854570
[TBL] [Abstract][Full Text] [Related]
15. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor.
Kroner PA; Foster PA; Fahs SA; Montgomery RR
Blood; 1996 Feb; 87(3):1013-21. PubMed ID: 8562925
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies against the human factor VIII von Willebrand molecule: characterization and potential for screening of von Willebrand patients.
Avner P; Arnaud D; Sultan Y; Maisonneuve P; Jeanneau C
Dev Biol Stand; 1984; 57():69-76. PubMed ID: 6084622
[TBL] [Abstract][Full Text] [Related]
17. Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain.
Hamer RJ; Koedam JA; Beeser-Visser NH; Bertina RM; Van Mourik JA; Sixma JJ
Eur J Biochem; 1987 Jul; 166(1):37-43. PubMed ID: 3109914
[TBL] [Abstract][Full Text] [Related]
18. Interaction between VWF and FVIII in treating VWD.
Miesbach W; Berntorp E
Eur J Haematol; 2015 Nov; 95(5):449-54. PubMed ID: 25605439
[TBL] [Abstract][Full Text] [Related]
19. Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease.
Kroner PA; Friedman KD; Fahs SA; Scott JP; Montgomery RR
J Biol Chem; 1991 Oct; 266(29):19146-9. PubMed ID: 1918030
[TBL] [Abstract][Full Text] [Related]
20. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody.
Fricke WA; Brinkhous KM; Garris JB; Roberts HR
Blood; 1985 Sep; 66(3):562-9. PubMed ID: 3927998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
